ESR1 and breast cancer: Overall, these data indicate that i) CHK1/CHK2 inhibition could be a valuable strategy to prevent ERα-positive BC progression, ii) CHK1 and ERα activations are correlated in ERα-positive BC cell lines, and iii) CHK1 downmodulation blocks the proliferation of ERα-positive BC cells.